# Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

Study · id `cardio:ct-nct05503953` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05503953](<https://clinicaltrials.gov/study/NCT05503953>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05503953

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.

## Technical summary

Registry record NCT05503953. Randomized; double masking; primary purpose treatment. Start 2022-09-13 (actual); primary completion 2025-06-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 318 participants (enrolled count; ClinicalTrials.gov record NCT05503953, source copy `cardio:ctgov-nct05503953-2026-09-10`, retrieved 2026-10-26)
- Started: 2022-09-13 (actual) (ClinicalTrials.gov record NCT05503953, source copy `cardio:ctgov-nct05503953-2026-09-10`, retrieved 2026-10-26)
- Primary completion: 2025-06-10 (actual) (ClinicalTrials.gov record NCT05503953, source copy `cardio:ctgov-nct05503953-2026-09-10`, retrieved 2026-10-26)
- Completion: 2025-06-10 (actual) (ClinicalTrials.gov record NCT05503953, source copy `cardio:ctgov-nct05503953-2026-09-10`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05503953, source copy `cardio:ctgov-nct05503953-2026-09-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05503953-2026-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
- Condition: Essential Hypertension
- Intervention (Drug): AGSAVI
- Intervention (Drug): AGLS
- Lead sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Daehwa Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd (`cardio:org-ahn-gook-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 64f62c803a129b889a29e157d93b6c4ff3b1fbcebf9b40e74839bbda0c085733
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
